Solid Biosciences Appoints New Chief Medical Officer
Ticker: SLDB · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1707502
| Field | Detail |
|---|---|
| Company | Solid Biosciences Inc. (SLDB) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
Related Tickers: MRNA
TL;DR
Solid Biosciences names Moderna exec Markham as new CMO.
AI Summary
Solid Biosciences Inc. announced on June 7, 2024, that it has appointed Dr. Paul B. Markham as its new Chief Medical Officer. Dr. Markham previously served as Senior Vice President and Chief Medical Officer at Moderna, Inc. The company also reported on matters submitted to a vote of security holders and filed financial statements and exhibits.
Why It Matters
The appointment of a new Chief Medical Officer can signal a shift in the company's strategic direction or a renewed focus on clinical development and regulatory affairs.
Risk Assessment
Risk Level: medium — The appointment of a new executive, especially a CMO, can introduce changes in strategy or execution, carrying inherent risks.
Key Players & Entities
- Solid Biosciences Inc. (company) — Registrant
- Dr. Paul B. Markham (person) — Newly appointed Chief Medical Officer
- Moderna, Inc. (company) — Previous employer of Dr. Markham
- June 7, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Solid Biosciences Inc.?
Dr. Paul B. Markham has been appointed as the new Chief Medical Officer of Solid Biosciences Inc.
What was Dr. Paul B. Markham's previous role?
Dr. Paul B. Markham previously served as Senior Vice President and Chief Medical Officer at Moderna, Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 7, 2024.
What other items are reported in this 8-K filing besides the officer appointment?
This 8-K filing also reports on the submission of matters to a vote of security holders and the filing of financial statements and exhibits.
In which state is Solid Biosciences Inc. incorporated?
Solid Biosciences Inc. is incorporated in Delaware.
Filing Stats: 1,181 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2024-06-11 16:22:02
Key Financial Figures
- $0.001 — ange on which registered Common Stock $0.001 par value per share SLDB The Nasdaq
Filing Documents
- d845618d8k.htm (8-K) — 49KB
- 0001193125-24-159143.txt ( ) — 170KB
- sldb-20240607.xsd (EX-101.SCH) — 3KB
- sldb-20240607_lab.xml (EX-101.LAB) — 18KB
- sldb-20240607_pre.xml (EX-101.PRE) — 11KB
- d845618d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: 99.1 Amended and Restated 2020 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 99.1 to the registrant's Registration Statement on Form S-8 (File No. 333-280116) filed with the Securities and Exchange Commission on June 11, 2024) 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 11, 2024 SOLID BIOSCIENCES INC. By: /s/ Alexander Cumbo Name: Alexander Cumbo Title: Chief Executive Officer